17 April 08 - Nathan Drona appointed as Non-Executive DirectorMr...

17 April 08 - Nathan Drona appointed as Non-Executive Director

Mr Drona added "I am delighted for the opportunity to the join the board of Avexa during this exciting time in its continued development. With Avexa's Phase III trial for apricitabine underway and as international interest in the company continues to grow, I think the company has tremendous potential for success."

http://www.avexa.com.au/freestyler/files/ASX%20Releases%20Avexa%20appoints%20US%20based%20Non%20Executive%20Director%2017%20April%2008.pdf



06 Oct 08 - Nathan Drona appointed as Chairman

"Mr. Drona is an investment banker in the life sciences industry and has successfully advised numerous companies in the U.S., Europe, and Australia in mergers and acquisitions. He has held a variety of senior management positions in the U.S., most recently as managing director of Challiss, based in New York."

http://www.avexa.com.au/freestyler/files/Avexa%20bolsters%20Board%20and%20appoints%20new%20Chairman%206%20Oct%2008.pdf



13 November 08 - Avexa presents data from ATC and Antibacterial Programs at two International Conferences

"ATC's successful Phase IIb trial positions the drug as the leading therapy for patients that are failing the first line of therapy used in the treatment of HIV. The Phase IIb trial enrolled patients with M184V mutant HIV, which is a
drug-resistant virus that results from the treatment of patients with Epivir, Combivir or Trizivir (currently
marketed by GlaxoSmithKline) or Emtriva?, Truvada and Atripla (currently marketed by Gilead Sciences)

http://www.avexa.com.au/freestyler/files/ICAAC%20and%20HIV9%2013%20Nov%202008.pdf



25 November 08 - AGM Chairman's address

"At this time, the jewel in our portfolio, ATC, is also perhaps the top clinical jewel in the entire Australian biotech industry."

http://www.avexa.com.au/freestyler/files/Chairmans%20Address%20AGM%2025%20November%202008.pdf



5 February 2009 - Avexa Releases Independent Expert Report

"Values ATC between $151m and $226m AUD"

http://www.avexa.com.au/freestyler/files/ICAAC%20and%20HIV9%2013%20Nov%202008.pdf



16 Mar 2009 - Avexa reports positive 96 week data for HIV drug apricitabine

"These data provide compelling evidence that ATC provides meaningful and sustained efficacy for at least two years, and in over 20 years of HIV drug development I cannot recall another drug where a signature resistance mutation is still absent after two years of dosing" said Dr
Jonathan Coates, Chief Scientific Officer. "Many patients who have difficulties with their HIV treatment regime start to forget or avoid taking all the doses, which obviously affects the control of the disease. The fact that 95 percent of patients are correctly taking ATC after two
years, without difficulty, is clear evidence that ATC can provide a safe, easy to take, effective and well tolerated addition to their therapy"

http://www.avexa.com.au/freestyler/files/Week%2096%20data.pdf



30 April 2009 - AVEXA RAISES $17M FOLLOWING CLOSURE OF 2009 RIGHTS ISSUE

http://www.avexa.com.au/freestyler/files/Rights%20Issue%20completed%20-%20$17m%20raised.pdf



30 November 2009 - Avexa to raise up to $11 Million through Share Placement and Share Purchase Plan

http://www.avexa.com.au/freestyler/files/Share%20Placement%20and%20Share%20Purchase%20Plan.pdf



4 February 2010 - AVEXA ANNOUNCES ATC PHASE III TOP LINE RESULTS

"The 24 week data from our Phase III trial has shown that ATC can improve clinical outcomes for patients suffering from HIV. This may position ATC as a complement to existing therapies in the HIV treatment landscape, including those recently approved," added Dr. Julian Chick, Chief Executive Officer.

http://www.avexa.com.au/freestyler/files/Avexa%20announces%20ATC%20phase%20III%20top%20line%20results.pdf



15 February 2010- AVEXA REPORTS POSITIVE PHASE IIb 144 WEEK DATA FOR HIV DRUG APRICITABINE (ATC)

"We are delighted that ATC continues to provide consistent, positive benefits for patients suffering from HIV," said Dr. Jonathan Coates, Chief Scientific Officer. "These results, along with the initial data from the Phase III study announced earlier this month, provide a clear indication of the medical value of ATC."

http://www.avexa.com.au/freestyler/files/Avexa%20reports%20positive%20phase%20IIb%20144%20week%20data%20for%20HIV%20drug%20apricitabine.pdf



AND THE EPILOGUE 10 May 2010 - AVEXA CLOSES APRICITABINE (ATC) PROGRAM

http://www.avexa.com.au/freestyler/files/Avexa%20closes%20apricitabine%20program.pdf